Inhibikase Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $0.00.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $250.93K.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $31.62K.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $44.14K.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $845.47K.
- Inhibikase Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $44.14K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $845.47K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $250.93K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $31.62K 10-Q · filed 2026-08-11 | |
| 2022-12-31 | $44.14K 10-K · filed 2023-03-31 | |
| 2022-03-31 | $44.14K 10-Q · filed 2023-11-14 | |
| 2021-09-30 | $44.14K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$43.30K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |